Intellia Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 80 U.S.-traded ETFs. NTLA has around 16.9M shares in the U.S. ETF market. The largest ETF holder of NTLA is the ARK Innovation ETF (ARKK), with approximately 6.66M shares. Investors may also find of interest that the ETF with the largest allocation to NTLA stock is Kelly CRISPR & Gene Editing Technology ETF (XDNA), with a portfolio weight of 10.96%. On average, U.S. ETFs allocate 0.76% of NTLA to their portfolios.
Additionally, NTLA is a favorite stock for Vanilla and Active ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with NTLA as a holding is the Avantis U.S. Equity ETF (AVUS), with a return of --.